Percutaneous Absorption and Pharmacokinetics of Eflornithine HCl 13.9% Cream in Women with Unwanted Facial Hair

Malhotra, Bimal; Noveck, Robert J.; Behr, Douglas; Palmisano, Maria

doi:10.1177/00912700122010951

Cited by 33 publications

(21 citation statements)

References 16 publications

(6 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Eflornithine hydrochloride, an inhibitor of the enzyme ornithine decarboxylase in human skin, has been approved for topical use in treating facial hirsutism, taking 6–8 weeks for its effect to be apparent 75. It can be combined with laser treatment.…”

Section: Management Of Pcosmentioning

confidence: 99%

Treatment options for polycystic ovary syndrome

Badawy¹,

Elnashar²

2011

IJWH

505

236

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women. The clinical manifestation of PCOS varies from a mild menstrual disorder to severe disturbance of reproductive and metabolic functions. Management of women with PCOS depends on the symptoms. These could be ovulatory dysfunction-related infertility, menstrual disorders, or androgen-related symptoms. Weight loss improves the endocrine profile and increases the likelihood of ovulation and pregnancy. Normalization of menstrual cycles and ovulation could occur with modest weight loss as little as 5% of the initial weight. The treatment of obesity includes modifications in lifestyle (diet and exercise) and medical and surgical treatment. In PCOS, anovulation relates to low follicle-stimulating hormone concentrations and the arrest of antral follicle growth in the final stages of maturation. This can be treated with medications such as clomiphene citrate, tamoxifen, aromatase inhibitors, metformin, glucocorticoids, or gonadotropins or surgically by laparoscopic ovarian drilling. In vitro fertilization will remain the last option to achieve pregnancy when others fail. Chronic anovulation over a long period of time is also associated with an increased risk of endometrial hyperplasia and carcinoma, which should be seriously investigated and treated. There are androgenic symptoms that will vary from patient to patient, such as hirsutism, acne, and/or alopecia. These are troublesome presentations to the patients and require adequate treatment. Alternative medicine has been emerging as one of the commonly practiced medicines for different health problems, including PCOS. This review underlines the contribution to the treatment of different symptoms.

show abstract

Section: Management Of Pcosmentioning

confidence: 99%

Treatment options for polycystic ovary syndrome

Badawy¹,

Elnashar²

2011

IJWH

505

236

View full text Add to dashboard Cite

show abstract

“…It is a potent, irreversible inhibitor of the enzyme ornithine decarboxylase, which is necessary for production of the polyamines that mediate cell migration, proliferation, and differentiation. [26] Binding of DHT to the androgen receptor is associated with stimulation of ornithine decarboxylase synthesis and proliferation of hair matrix cells. The cream is applied to the face twice a day.…”

Section: Treatmentmentioning

confidence: 99%

Hirsutism: Evaluation and treatment

Sachdeva¹

2010

Indian J Dermatol

View full text Add to dashboard Cite

Hirsutism is a common clinical condition seen in female patients of all ages. It affects around 5-10% of the women and is a common presenting complaint in the dermatological out patient department for cosmetic reasons. The cause is mainly hyperandrogeneism, which may be ovarian or adrenal. It may be part of a rare metabolic syndrome, drug induced, or just idiopathic. Hirsutism has a huge psychosocial impact, especially in the young females. This article reviews the current evaluation guidelines and management of hirsutism.

show abstract

“…infusion for the treatment of trypanosomiasis in adults and children, even when given at high doses (Chappuis, Udayraj, Stietenroth, Meussen, & Bovier 2005; Priotto, Pinoges, Fursa, Burke, Nicolay, Grillet, Hewison, & Balasegaram 2008). Transdermal absorption is usually very limited (< 1%), and most of the absorbed eflornithine is excreted unchanged in the urine (Malhotra et al 2001). The improved hair growth inhibition by the combined treatment with microneedles and eflornithine may also allow less frequent application/exposure.…”

Section: Resultsmentioning

confidence: 99%

A method to improve the efficacy of topical eflornithine hydrochloride cream

et al. 2014

View full text Add to dashboard Cite

Context Facial hirsutism is a cosmetic concern for women and can lead to significant anxiety and lack of self-esteem. Eflornithine cream is indicated for the treatment of facial hirsutism. However, limited success rate and overall patient’s satisfaction, even with a long-term and high frequency application, leave room for improvement. Objective The objective of this study is to test the effect of microneedle treatment on the in vitro skin permeation and the in vivo efficacy of eflornithine cream in a mouse model. Materials and method In vitro permeation study of eflornithine was performed using Franz diffusion cell. In vivo efficacy study was performed in a mouse model by monitoring the re-growth of hair in the lower dorsal skin of mice after the eflornithine cream was applied onto an area pretreated with microneedles. The skin and the hair follicles in the treated area were also examined histologically. Results and discussion The hair growth inhibitory activity of eflornithine was significantly enhanced when the eflornithine cream was applied onto a mouse skin area pretreated with microneedles, most likely because the micropores created by microneedles allowed the permeation of eflornithine into the skin, as confirmed in an in vitro permeation study. Immunohistochemistry data revealed that cell proliferation in the skin and hair follicles was also significantly inhibited when the eflornithine cream was applied onto a skin area pretreated with microneedles. Conclusion The integration of microneedle treatment into topical eflornithine therapy represents a potentially viable approach to increase eflornithine’s ability to inhibit hair growth.

show abstract

Percutaneous Absorption and Pharmacokinetics of Eflornithine HCl 13.9% Cream in Women with Unwanted Facial Hair

Cited by 33 publications

References 16 publications

Treatment options for polycystic ovary syndrome

Treatment options for polycystic ovary syndrome

Hirsutism: Evaluation and treatment

A method to improve the efficacy of topical eflornithine hydrochloride cream

Contact Info

Product

Resources

About